[CAS NO. 853426-35-4] Blinatumomab

Ships within

Stock

Price

Qty

Total

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Blinatumomab]

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00560794	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	January 2008	Phase 2
NCT04723342	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Childhood Acute Lymphoblastic Leukemia	February 1, 2020	Not Applicable
NCT02790515	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myeloid Sarcoma\|Chronic Myeloid Leukemia (CML)\|Juvenile Myelomonocytic Leukemia (JMML)\|Myelodysplastic Syndrome (MDS)\|Non-Hodgkin Lymphoma (NHL)	July 14, 2016	Phase 2
NCT02961881	Amgen	Non-Hodgkin´s Lymphoma	September 18, 2017	Phase 1
NCT04524455	Amgen	Acute Lymphoblastic Leukemia	October 2, 2020	Phase 1
NCT04554485	Institute of Hematology and Blood Transfusion, Czech Republic\|CZECRIN - Czech Clinical Research Infrastructure Network	Lymphoblastic Leukemia, Acute, Adult\|Ph Negative ALL\|Newly Diagnosed	May 9, 2019	Phase 2
NCT04827745	University of Maryland, Baltimore	Mixed Phenotype Acute Leukemia (MPAL)\|Measurable Residual Disease (MRD)	June 11, 2021	Phase 2
NCT04506086	Amgen	B-precursor Acute Lymphoblastic Leukemia	August 26, 2021	Phase 4
NCT03849651	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndromes (MDS)\|NK-Cell Leukemia\|Hodgkin Lymphoma\|Non Hodgkin Lymphoma (NHL)\|Juvenile Myelomonocytic Leukemia (JMML)\|Chronic Myeloid Leukemia (CML)	January 31, 2019	Phase 2
NCT03121534	M.D. Anderson Cancer Center\|Amgen	Hematopoietic+Lymphoid Cancer\|Richter´s Transformation	June 22, 2017	Phase 2
NCT01741792	Amgen Research (Munich) GmbH	Diffuse Large B-cell Lymphoma	July 2012	Phase 2
NCT03023878	Amgen	High-risk Diffuse Large B-Cell Lymphoma	March 13, 2017	Phase 2
NCT04530565	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	October 14, 2020	Phase 3
NCT03518112	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Philadelphia Chromosome Negative\|Recurrent B Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia	April 18, 2018	Phase 2
NCT01371630	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative\|Burkitt-Like Lymphoma With 11q Aberration\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Burkitt Lymphoma\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Burkitt Lymphoma	August 26, 2011	Phase 1\|Phase 2
NCT04307576	Mats Heyman\|The Swedish Research Council\|The Swedish Childhood Cancer Foundation\|Pfizer\|Servier\|NordForsk\|Aamu Pediatric Cancer Foundation\|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany\|Clinical Trial Center North (CTC North GmbH & Co. KG)\|Belgium Health Care Knowledge Centre\|Karolinska Institutet\|Cancer Research UK\|Fundação Rui Osório de Castro\|Acreditar - Associação de Pais e Amigos das Crianças com Cancro\|Grupo Português De Leucemias Pediátricas\|Amgen\|Nova Laboratories Limited\|Danish Child Cancer Foundation\|Danish Cancer Society\|The Novo Nordic Foundation\|Karolinska University Hospital	Leukemia, Acute Lymphoblastic	July 13, 2020	Phase 3
NCT02879695	National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Mixed Phenotype Acute Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Mixed Phenotype Acute Leukemia	May 5, 2017	Phase 1
NCT03072771	Washington University School of Medicine\|Amgen	Diffuse Large B Cell Lymphoma	August 1, 2017	Phase 1
NCT04994717	Amgen	Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)	November 2, 2021	Phase 3
NCT02412306	Amgen\|Amgen Astellas Biopharma K.K.	Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia	June 4, 2015	Phase 1\|Phase 2
NCT04556084	Michael Burke\|Amgen\|Medical College of Wisconsin	B-cell Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Relapsed B-cell Acute Lymphoblastic Leukemia	January 1, 2021	Phase 2
NCT03147612	M.D. Anderson Cancer Center	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia With BCR-ABL1\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	February 8, 2018	Phase 2
NCT05192889	St. Jude Children´s Research Hospital\|AbbVie	Refractory Acute Lymphoblastic Leukemia\|Relapsed Acute Lymphoblastic Leukemia	August 25, 2022	Phase 1\|Phase 2
NCT04448834	Dorothy Sipkins, MD, PhD\|Amgen\|Acrotech Biopharma Inc.\|Duke University	B-cell Acute Lymphoblastic Leukemia	January 2022	Phase 2
NCT03117751	St. Jude Children´s Research Hospital\|Incyte Corporation\|Amgen\|Servier	Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Lymphoma	March 29, 2017	Phase 2\|Phase 3
NCT03709719	Assistance Publique - Hôpitaux de Paris	Acute Lymphoblastic Leukemia, Adult B-Cell	October 20, 2018	Phase 2
NCT03914625	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma\|Down Syndrome	June 28, 2019	Phase 3
NCT03523429	PETHEMA Foundation	Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL	June 30, 2018	Phase 2
NCT02744768	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia	May 31, 2017	Phase 2
NCT05182385	Goethe University\|University Hospital Schleswig-Holstein	ALL, Recurrent, Adult	December 15, 2021	Phase 1\|Phase 2
NCT02101853	National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia	December 8, 2014	Phase 3
NCT03739814	National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative\|Recurrent B Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia	November 16, 2018	Phase 2
NCT02000427	Amgen	Relapsed+Refractory Philadelphia Positive B-precursor ALL	January 3, 2014	Phase 2
NCT02003222	National Cancer Institute (NCI)\|Canadian Cancer Trials Group	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	December 23, 2013	Phase 3
NCT02393859	Amgen	Leukemia, Acute Lymphoblastic	November 10, 2015	Phase 3
NCT04044560	University of British Columbia\|Amgen	B-cell Adult Acute Lymphoblastic Leukemia\|Stem Cell Leukemia\|Minimal Residual Disease	September 8, 2020	Phase 2
NCT02568553	National Cancer Institute (NCI)	Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Grade 3a Follicular Lymphoma\|Recurrent Grade 3b Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mediastinal Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Refractory Burkitt Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma\|Refractory Grade 1 Follicular Lymphoma\|Refractory Grade 2 Follicular Lymphoma\|Refractory Grade 3 Follicular Lymphoma\|Refractory Grade 3a Follicular Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Mediastinal Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Small Lymphocytic Lymphoma	June 14, 2016	Phase 1
NCT04722848	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)\|ALL, Adult\|Philadelphia-Positive ALL	September 8, 2021	Phase 3
NCT03751709	Cedars-Sinai Medical Center\|Amgen	B-Cell Acute Lymphoblastic Leukaemia\|ALL, Adult\|B-ALL	February 14, 2020	Phase 1
NCT01466179	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	December 2011	Phase 2
NCT03512405	City of Hope Medical Center\|National Cancer Institute (NCI)	CD19 Positive\|Philadelphia Chromosome Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	August 2, 2019	Phase 1\|Phase 2
NCT04521231	Amgen	B Cell Precursor Acute Lymphoblastic Leukemia	January 4, 2021	Phase 1
NCT03173430	Abramson Cancer Center of the University of Pennsylvania	Multiple Myeloma	May 27, 2017	Early Phase 1
NCT03318770	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoblastic Leukemia	May 10, 2019
NCT04688983	Cardiff University	Acute Lymphoblastic Leukemia, Adult	January 2021	Phase 2
NCT03541083	Stichting Hemato-Oncologie voor Volwassenen Nederland	ALL, Adult	June 4, 2018	Phase 2
NCT02811679	Massachusetts General Hospital\|Amgen	Non-Hodgkin Lymphoma	August 2016	Phase 2
NCT02187354	Amgen	Relapsed+Refractory B-Precursor Acute Lymphoblastic Leukemia
NCT05559450	The First Affiliated Hospital of Soochow University\|Fujian Medical University Union Hospital\|Zhongda Hospital\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|The First People´s Hospital of Changzhou\|Wuxi People´s Hospital\|First Affiliated Hospital of Wannan Medical College	B-cell Acute Lymphoblastic Leukemia	February 1, 2022	Phase 2
NCT03982992	Ludwig-Maximilians - University of Munich\|Amgen	B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation\|B-Cell Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Lymphoblastic Leukemia, Adult	June 1, 2019	Phase 2
NCT02807883	M.D. Anderson Cancer Center\|Amgen	Acute Lymphoblastic Leukemia	August 2016	Phase 2
NCT03823365	A.O. Ospedale Papa Giovanni XXIII	Indolent Non-Hodgkin Lymphomas+Chronic Lymphocytic Leukemia	December 17, 2018	Phase 1
NCT04604691	Seoul National University Hospital\|Amgen	Pediatric ALL, B Cell\|Minimal Residual Disease	February 18, 2022	Phase 1
NCT03298412	Amgen	High-risk Diffuse Large B-cell Lymphoma	May 23, 2018	Phase 2
NCT05327894	Princess Maxima Center for Pediatric Oncology\|Amgen Europe B.V\|University of Milano Bicocca	Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia	September 2022	Phase 3
NCT03643276	Martin Schrappe\|Deutsche Krebshilfe e.V., Bonn (Germany)\|University Hospital Schleswig-Holstein	Acute Lymphoblastic Leukemia, Pediatric	July 15, 2018	Phase 3
NCT04334993	Israeli Medical Association	Philadelphia-Negative ALL\|High-Risk Cancer	January 1, 2021	Phase 2
NCT01207388	Amgen Research (Munich) GmbH	B-cell Acute Lymphoblastic Leukemia	November 2010	Phase 2
NCT03114865	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Amgen	Acute Lymphoblastic Leukemia\|B-cell Non Hodgkin Lymphoma\|Pre B-Cell Acute Lymphoblastic Leukaemia	September 5, 2017	Phase 1\|Phase 2
NCT02143414	National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	January 12, 2015	Phase 2
NCT03367299	Gruppo Italiano Malattie EMatologiche dell´Adulto	Acute Lymphoid Leukemia\|Philadelphia Chromosome-Negative B-Cell Precursor	June 8, 2018	Phase 2
NCT01209286	Amgen Research (Munich) GmbH	B-ALL	October 2010	Phase 2
NCT03480438	Goethe University	B-Precursor ALL	June 1, 2018	Phase 2
NCT04785547	Prof. Christina Peters\|Amgen\|St. Anna Kinderkrebsforschung	ALL, Childhood\|Minimal Residual Disease	December 17, 2020	Phase 2
NCT03931642	French Innovative Leukemia Organisation\|Amgen	Richter Syndrome	July 5, 2019	Phase 2
NCT03605589	Children´s Hospital Medical Center, Cincinnati	Leukemia, B-cell\|Lymphoma, B-Cell	September 27, 2018	Phase 1
NCT02013167	Amgen	Relapsed+Refractory B-precursor Acute Lymphoblastic Leukemia	January 3, 2014	Phase 3
NCT02877303	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma	November 1, 2016	Phase 2
NCT02997761	Brian Jonas\|National Cancer Institute (NCI)\|Pharmacyclics LLC.\|University of California, Davis	Adult B Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive	June 27, 2017	Phase 2
NCT02910063	Amgen	B-Cell Non Hodgkin Lymphoma	January 23, 2017	Phase 2\|Phase 3
NCT00274742	Amgen Research (Munich) GmbH	Non-Hodgkin´s Lymphoma, Relapsed	June 2004	Phase 1
NCT05519579	Northside Hospital, Inc.	Acute Lymphoblastic Leukemia	November 1, 2022	Phase 2
NCT04260022	Ascentage Pharma Group Inc.	Leukemia, Myeloid, Chronic\|Myeloid Leukemia\|Chronic Myeloid Leukemia\|Philadelphia Positive Acute Lymphoblastic Leukemia\|B Cell Precursor Type Acute Leukemia	January 9, 2020	Phase 1
NCT04546399	National Cancer Institute (NCI)	Down Syndrome\|Recurrent B Acute Lymphoblastic Leukemia	December 4, 2020	Phase 2
NCT04746209	Medical College of Wisconsin\|Amgen\|University of Wisconsin, Madison	B-cell Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|B-Cell ALL, Childhood	February 1, 2021	Phase 2
NCT03263572	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Amgen\|Takeda	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|BCR-ABL1 Fusion Protein Expression\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Philadelphia Chromosome Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|t(9;22)	November 29, 2017	Phase 2
NCT03340766	Amgen\|Merck Sharp & Dohme LLC	Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)	March 16, 2018	Phase 1
NCT03160079	University of California, San Diego\|Merck Sharp & Dohme LLC\|Amgen	B-Cell Acute Lymphoblastic Leukemia, Adult	August 4, 2017	Phase 1\|Phase 2
NCT01471782	Amgen Research (Munich) GmbH	Acute Lymphoblastic Leukemia	January 2012	Phase 1\|Phase 2
NCT03109093	Goethe University	ALL, Recurrent, Adult	March 15, 2017	Phase 2
NCT02458014	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Lymphoblastic Leukemia in Complete Remission\|B Acute Lymphoblastic Leukemia\|Minimal Residual Disease\|Philadelphia Chromosome Positive	September 14, 2015	Phase 2
NCT03628053	Novartis Pharmaceuticals\|Novartis	Acute Lymphoblastic Leukemia	June 5, 2020	Phase 3
NCT03476239	Amgen	Acute Lymphoblastic Leukemia	October 18, 2017	Phase 3
NCT04329325	Memorial Sloan Kettering Cancer Center\|Amgen	Acute Lymphoblastic Leukemia\|Philadelphia Chromosome-Positive	March 30, 2020	Phase 2
NCT05557110	Chen Suning\|The First Affiliated Hospital of Soochow University	B Acute Lymphoblastic Leukemia	September 8, 2022	Phase 2

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Catalog:	HY-P9963
Brand:	MCE
CAS:	853426-35-4

[CAS NO. 853426-35-4] Blinatumomab

Overview

Summary

Clinical Trial

Appearance

Shipping

Storage

References